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CONCLUSIONS: Resource utilization and costs associated with migraine increased
with greater headache frequency. Treatments that reduce headache frequency
have the potential to have a positive economic impact by reducing costs associated
with migraine care.
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OBJECTIVES: To conduct a pilot study examining the validity and reliability of a
paper-based standard gamble (PSG) instrument and to administer the validated
PSG among persons with hemophilia B enrolled in the Hemophilia Utilization
Group Study (HUGS-Vb). METHODS: Fifteen pharmacy students were enrolled in
this pilot. We presented a hypothetical scenario describing a patient with severe
hemophilia to each participant, followed by three tests: (1)Standard Gamble (SG)
using the probability wheel, (2)PSG and (3)Visual Analog Scale (VAS), each admin-
istered in random order. PSG was re-administered after two weeks to assess test-
retest reliability. The validated PSGwas subsequently administered to participants
enrolled in HUGS-Vb, a prospective, multicenter study collecting utilization and
other data associated with hemophilia B in the United States. Participants or their
parent(s) completed a demographic questionnaire, the PSG and the EQ-5D. A PSG
scenario based on actual demographic and clinical characteristics was created for
each participant. Paired t-test, Spearman rank correlation coefficient (rho) and
intra-class correlation coefficient (ICC) were used to assess the convergent validity
and reliability of the instrument. RESULTS:Mean SG, PSG and VAS in the pilot were
0.790.15, 0.820.14 and 66.823.0, respectively. The mean difference between
PSG and SG did not differ significantly from 0 (p0.124). PSG was significantly
correlated with SG (rho0.769, p0.0008) and VAS (rho0.534, p0.0405). PSG re-
test score was 0.790.13 and test-retest ICC was 0.85 (95% CI: 0.63-0.94; p0.0001).
Of 71 HUGS-Vb participants, 32 (45%) were adults; 38 (54%) had severe hemophilia.
Mean agewas 21.8 years (range 2-61). Mean PSG andVAS scoreswere 0.910.15 and
84.414.6 respectively, with weak correlation between the two (rho0.242,
p0.0452) in the full sample. Adult PSG and EQ-5D scores were 0.870.18 and
0.850.16 respectively, with correlation rho0.348 (p0.0506). CONCLUSIONS: A
paper-based standard gamble instrument may be a valid, reliable alternative to SG
for measuring health utility in hemophilia patients.
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OBJECTIVES: To map the Insomnia Severity Index (ISI) to the EQ-5D utilities.
METHODS: A cross-sectional, online survey was conducted among adult US resi-
dents with self-reported sleep problems. Respondents provided demographic, co-
morbidity, previous-night sleep-related information and, completed the EQ-5Dand
the ISI, a seven-item instrument measuring perceived insomnia severity. Each ISI
item is scored from 0-4 with minimum total score of 0 (no insomnia) and a maxi-
mum of 28 (most severe insomnia). Respondents can be classified into four ISI
categories (0-7: no clinically significant insomnia; 8-14 subthreshold insomnia; 15-
21: moderate insomnia; 22-28: severe insomnia). Generalized linear models were
used to map the seven ISI items (Model 1), the ISI summary scores (Model 2), and
the four ISI clinical categories (Model 3) onto EQ-5D utilities. Predictions were esti-
mated using 50/50 split sample validation. Model fits were assessed using mean
squared error (MSE) and distributional quality of predicted values. RESULTS: Re-
spondents (n2,842) were predominantly middle-aged, female, Caucasian, with
1 comorbidity. Mean sleep duration was 7.8 (1.9) hours, mean ISI score was 14.1
(4.8). Mean predicted utilities were (0.7650.08) across all models, overlapping
with observed utilities (0.7650.18). Using Model 1, predicted utilities increased
linearly with improving ISI (0.493 if ISI28; 1.00 if ISI0, p0.01). In Model 2, each
unit decrease in ISI summary was associated with a 0.022 (p0.001) increase in
utility. Predicted utilities were 0.868, 0.809, 0.722 and 0.579 for no clinical, sub-
threshold, moderate and severe insomnia, respectively (Model 3). The overall MSEs
betweenpredictedandobservedutilitiesweregood inallmodels (Model I: 0.025,Model
II & III: 0.026), especiallywhenpredicting utilities0.40 (MSEs: 0.016-0.056).MSEswere
higher when predicting lower utilities (MSEs: 0.138-0.156). CONCLUSIONS: Linear re-
lationshipswere found between EQ-5Dutilities and the ISI. These relationships can
be used to estimate the impact of insomnia-associated treatment effects on utili-
ties.
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OBJECTIVES: To create and implement a secure web-based research program
that collects and tracks validated patient-reported outcomes (PROs) for multiple
sclerosis (MS) patients and their healthcare providers (HCP).METHODS: The My
MS Health program can be accessed through a HIPAA secure website, www.
mymshealth.org. A pilot study to evaluate the My MS Health program has been
IRB-approved. Assessment of inclusion/exclusion criteria, enrollment, and in-
formed consent with an electronic signature occurs through this secure web-
site. Enrolled patients are prompted to complete a series of nine validated PRO
surveys that measure MS specific symptom status, functional status, and qual-
ity-of-life, and results are immediately available. Patients may elect to give their
HCP access to their real-time PRO results electronically. Aggregate data analysis
can also be performed on the collected PRO data. RESULTS: In this ongoing study,
927 patients were enrolled and 122 were eligible to participate in the program
evaluation survey at three months. Scores were measured on 5-point Likert scales
with a range of low agreement (1) to high agreement (5) and scores greater than or
equal to 3 signify agreement. Overall, 93% felt the amount of time it took to answer
the surveys was just right, and 91% felt the website was easy to use (4.51.05). In
addition, 92% reported they would likely continue participating in the program
(4.081.11) and 78% reported they would likely recommendMyMS Health to others
(3.851.48). CONCLUSIONS: Preliminary results indicate My MS Health is an effi-
cient and user friendly technology platform that patients will continue to use.
Future evaluations will assess the impact of using the program on patient and HCP
communication.
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OBJECTIVES: To assess the relationship between internal locus of control (ILOC)
and treatment satisfaction in MS patients after 1 year of natalizumab treatment.
METHODS: MS patients completed the Treatment Satisfaction Questionnaire for
Medication (TSQM) prior to natalizumab initiation (BL) and after the 12th natali-
zumab infusion. Effectiveness, Convenience and Global Satisfaction subscale
scores range from 0 to 100; higher scores indicate higher satisfaction. ILOC was
assessed at BL and after the 12th infusion using the ILOC subscale of the Multidi-
mensional Health Locus of Control questionnaire. Subscale scores range from 6 to
36; higher scores indicate greater ILOC. Correlation analysis and regressionmodels
evaluated the relationship between ILOC and satisfaction with natalizumab after
12 infusions, controlling for BL patient characteristics. RESULTS: A total of 333
patients (mean age 46.810.4 years and median of 9 years since MS diagnosis)
completed all assessments. BL and 12th ILOCwas correlatedwith BL and 12th Global
Satisfaction (r0.13, p0.0247 and r0.27, p0.0001, respectively) and Effective-
ness (r0.23, p0.0001 and r0.29, p0.0001, respectively); 12th ILOC was corre-
lated with 12th convenience (r0.12, p0.0373). Regression model results showed
that, after controlling for covariates, higher ILOC predicted greater global satisfac-
tion (p0.003), effectiveness (p0.001) and convenience (p0.017) with natali-
zumab after 12 infusions. CONCLUSIONS: Patients with MS with stronger internal
beliefs about having control over their own health have higher satisfaction with
natalizumab treatment after 12 infusions. Interventions supporting and reinforc-
ing patients’ health beliefs may have a positive impact on overall treatment satis-
faction resulting in improved treatment adherence.
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OBJECTIVES: The Short Parkinson’s Evaluation Scale/Scales for Outcomes in Par-
kinson’s disease (SPES/SCOPA) was developed as a reliable and valid scale to eval-
uate motor impairment in Parkinson’s disease (PD) patients and can be completed
in less time than the gold standard Unified Parkinson’s Disease Rating Scale (UP-
DRS). This study aimed to further investigate the reliability and validity of the
SPES/SCOPA motor clinical examination, as relatively little research in the US has
done so.METHODS: The BRAVURA study was designed to investigate order effects
associated with the UPDRS motor examination at 2 centers in the US. Patients,
stratified by center and previous Hoehn and Yahr (H&Y) stage, were randomly
assigned to 1 of 2 UPDRS item sequences. All scale evaluations occurred during a
single clinic visit. In addition to the 8-item SPES/SCOPAmotor clinical examination
and the 14-itemUPDRSmotor examination, scales included current H&Y stage and
patient- and physician-rated Schwab and England Activities of Daily Living (ADL).
Datawere analyzed using Cronbach’s alpha and Spearman’s correlation. RESULTS:
Complete data were available for 112 patients (mean time from diagnosis  6.4
years). Relationships among the scales were comparable across the 2 experimental
groups, thus data were pooled for these analyses; SPES/SCOPA mean score  9.5
(SD  5.2). The SPES/SCOPA demonstrated good internal reliability (alpha  0.79).
Construct validity was supported with the SPES/SCOPA correlating 0.76 with the
UPDRS. Furthermore, the SPES/SCOPA correlated 0.47 with current H&Y stage and
0.39, 0.45 with patient- and physician-rated ADL, respectively. CONCLUSIONS:
In this US sample of PD patients with varied disease severity, the SPES/SCOPA
exhibited good psychometrics, including evidence of construct validity with the
current standard of motor impairment measurement. The SPES/SCOPA also had
good internal consistency and correlated with 3 broad evaluations of disease dis-
ability in a similar fashion to the UPDRS.
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